Navigation Links
ImQuest Presents Data on the Anti-Hepatitis B Virus Activity of Pyrimidinediones at the 13th ISVHLD Meeting in Washington D.C.
Date:3/31/2009

FREDERICK, Md., March 31 /PRNewswire/ -- ImQuest Life Sciences today presented important new results on the continued development of the pyrimidinedione small molecules as antiviral agents at the 13th International Symposium on Viral Hepatitis and Liver Disease meeting held last week in Washington D.C. ImQuest's screening efforts have identified ten pyrimidinediones as inhibitors of HBV replication, with two compounds yielding potent inhibition of HBV replication at sub-micromolar concentration levels. The two lead molecules, IQP-0568 and IQP-0589 have also been shown to be active non-nucleoside inhibitors of HIV replication, but inactive against a panel of other RNA and DNA viruses, suggesting specificity for antiviral activity against viruses that encode a reverse transcriptase. These studies provide a fundamental structural basis for the development of first in class non-nucleoside inhibitors of HBV replication. The data were presented by Todd B. Parsley, Ph.D., Director of Hepatitis Virus Research as a component of a session entitled, "Experimental Approaches to Therapy of HBV." The studies included ImQuest co-authors Lu Yang, MD and Robert W. Buckheit, Jr., Ph.D.

"These results reveal the potential for the development of the pyrimidinediones as a first in class non-nucleoside inhibitor of HBV infection," said Dr. Buckheit, Executive Vice President and Chief Scientific Officer of ImQuest Life Sciences. "These studies are also intriguing from the perspective of potential treatment options for patients co-infected with HBV and HIV."

The research presented continues the scientific partnership between ImQuest Life Sciences and Samjin Pharmaceuticals as a component of their joint efforts to develop new and novel anti-infective and anti-cancer therapeutics.

ImQuest Life Sciences, a privately held U.S. company located in Frederick, Maryland specializes in early stage drug development of novel compounds for the treatment of infectious disease and cancer. ImQuest BioSciences, also located in Frederick, Maryland, is a leading provider of anti-infective therapeutic and microbicide development services to the biotechnology and pharmaceutical industry.

    For further information regarding this press release please contact:

    Robert W. Buckheit, Jr., Ph.D.
    Executive Vice President and Chief Scientific Officer
    ImQuest Life Sciences, Inc.
    301-696-0274
    rbuckheit@imquest.com


'/>"/>
SOURCE ImQuest Life Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImQuest Presentations at CROI Report Significant Advances in Therapeutic and Microbicide Product Development Programs
2. ImQuest Presents IND-Enabling Safety Pharmacology and Pharmacokinetic Data for the Therapeutic HIV Compound IQP-0410 at Conference on Retroviruses and Opportunistic Infections
3. ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission
4. ImQuest Awarded SBIR Grant to Define the Mechanism of Action of Their Lead Anti-HIV Therapeutic Compound IQP-0410
5. Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting
6. EPA Presents Initial Results from Caliper Life Sciences ToxCast Screening Effort
7. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
8. Agendia Presents Data Supporting MammaPrints Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer Conference
9. Commonwealth Biotechnologies Presents Data at Forensic Sciences Meeting Confirming Benefits of ZyGEMs DNA Extraction Technology
10. Prous Institute Presents Innovative Approach to Drug Discovery
11. PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... ... firm is utilizing its extensive experience with Health Economics and Outcomes Research (HEOR) ... Health Record data. In 2014, US healthcare spending exceeded $3.0 trillion with nearly ...
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... Today Aether ... a project, funded by a Bill and Melinda Gates Foundation grant, to ... Bill & Melinda Gates Foundation, also known as the Gates Foundation, is said to ...
(Date:8/18/2017)... ... August 18, 2017 , ... OAI, a ... MEMS, and Microfluidics Industries, announces the new Model 800E front and backside, semi-automatic ... automated production mask aligners. OAI has already received and installed several orders ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... cancer research and personalized medicine, today announced the launch of a new breast ... Missouri. The study’s goal is to evaluate the potential for early detection of ...
Breaking Biology Technology:
(Date:4/11/2017)... DUBLIN , Apr. 11, 2017 Research ... Tracking Market 2017-2021" report to their offering. ... The global eye tracking market to grow at ... The report, Global Eye Tracking Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
Breaking Biology News(10 mins):